Press Releases April 29, 2026 05:01 PM

Centerra Gold Announces Quarterly Dividend of C$0.07 per Common Share

Centerra Gold declares quarterly dividend of C$0.07 per share, reinforcing shareholder returns amid stable operations.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CGAU

Centerra Gold Inc. announced a quarterly dividend of C$0.07 per common share, totaling approximately C$13.9 million (US$10.0 million), payable on June 4, 2026. The dividend aligns with Centerra's dividend policy, which considers operating results, cash flow, financial conditions, and capital requirements. Centerra operates gold and copper mining properties in North America and Türkiye, with shares trading on both the TSX and NYSE.

Centerra Gold Announces Quarterly Dividend of C$0.07 per Common Share
CGAU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Board approved quarterly dividend of C$0.07 per share, payable June 4, 2026.
  • Dividend reflects Centerra's positive cash flow and stable financial position.
  • Company operates key mining assets in Canada and Türkiye, supporting diversified gold and copper production.

TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) announced today that its Board of Directors has approved a quarterly dividend of C$0.07 per common share – approximately C$13.9 million or US$10.0 million in aggregate. The quarterly dividend is payable on June 4, 2026, to shareholders of record as of the close of business on May 21, 2026. The dividend is an eligible dividend for Canadian income tax purposes.

In accordance with Centerra’s dividend policy, the timing and quantum of dividends are to be determined by the Board of Directors from time-to-time based on, among other things, the Company’s operating results, cash flow and financial conditions, current and anticipated capital requirements, and general business conditions.

About Centerra Gold

Centerra Gold Inc. is a Canadian-based gold mining company focused on operating, developing, exploring and acquiring gold and copper properties in North America, Türkiye, and other markets worldwide. Centerra operates two mines: the Mount Milligan Mine in British Columbia, Canada, and the Öksüt Mine in Türkiye. The Company also owns the Kemess Project in British Columbia, Canada, the Goldfield Project in Nevada, United States, and owns and operates the Molybdenum Business Unit in the United States and Canada. Centerra’s shares trade on the Toronto Stock Exchange (“TSX”) under the symbol CG and on the New York Stock Exchange (“NYSE”) under the symbol CGAU. The Company is based in Toronto, Ontario, Canada.

For more information:

Lisa Wilkinson
Vice President, Investor Relations & Corporate Communications
(416) 204-3780
Lisa.Wilkinson@centerragold.com

Additional information on Centerra is available on the Company’s website at www.centerragold.com, on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.


Risks

  • Dividend payments depend on future operating results and financial conditions, which may fluctuate.
  • Commodity price volatility could impact cash flow and dividend ability.
  • Geopolitical and operational risks in mining regions could affect production and financial performance.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026